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ABSTRACT
Objective To develop a standardised set of economic 
parameters (core economic parameter set) for economic 
evaluations in asthma studies.
Design A systematic literature review and an analytical 
framework.
Outcome measures Economic parameters used to 
evaluate costs and cost- effectiveness of healthcare 
interventions for people with asthma.
Data sources PubMed, the Cochrane Database of 
Systematic Reviews, the National Health Service Economic 
Evaluation Database, the Database of Abstracts of Reviews 
of Effects and the Health Technology Aaaessment Library 
starting from 1990.
Review methods Research methods were based on the 
realist review methodology and included a number of non- 
sequential, iterative and overlapping components, such as 
developing an analytical framework for the realist review; 
systematic literature review of economic parameters; 
identifying and categorising economic parameters; 
producing preliminary list of core economic parameters.
Results Database searches found 2531 publications of 
which 224 were included in the systematic review. We 
identified 65 economic parameters that were categorised 
into 11 groups to enable the realist synthesis. Parameters 
related to secondary care, primary care, medication use, 
emergency care and work productivity comprised 84% 
of all economic parameters. An analytical framework 
was used to investigate the rationale behind the choices 
of economic parameters in these studies. The main 
framework domains included type of intervention, research 
population, study design, study setting and a stakeholder’s 
perspective.
Conclusion Past research thus suggests that in asthma 
study parameters depicting the use of secondary care, 
primary care, medication, emergency care and work 
productivity can be considered as core economic 
parameters, since they apply to different types of studies. 
Parameters including diagnostics, healthcare delivery, 
school activity, informal care, medical devices and health 
utility apply to a particular type of study (or research 
question), and thus can be recommended as supplemental 
parameters.
PROSPERO registration number CRD42017067867.
BACKGROUND
Asthma is a common disease characterised 
by recurrent attacks of breathlessness and 
wheezing. It affects 5.4 million people in the 
UK: 1 in 11 children and 1 in 12 adults.1 2 
According to the International Clinical Trials 
Registry Platform,3 there are currently 4391 
registered trials for asthma. Many of these 
studies report different health outcomes, 
which have consequently made it difficult 
for researchers to compare the available 
evidence.4 5 Selecting appropriate health 
outcomes at the study design stage is essen-
tial to ensure comparability between different 
studies, to reduce heterogeneity between 
reported outcomes, to facilitate evidence 
synthesis and to minimise the risk of outcome 
reporting bias.4–6
In the last decade, there has been general 
move towards developing core outcome sets 
for use in clinical trials. The Core Outcome 
Measures in Effectiveness Trials (COMET) 
Initiative, launched in 2010, brings together 
academics, clinical researchers, research 
funders, health service users, policy makers 
and trial regulators interested in developing 
and using standardised sets of outcome 
measures. The COMET initiative provides a 
Strengths and limitations of this study
 ► Research methods were based on the realist review 
methodology.
 ► We developed an analytical framework to investi-
gate the rationale behind the choices of economic 
parameters in asthma studies.
 ► We identified the most frequently used economic 
parameters.
 ► We derived a preliminary list of core economic 
parameters.
 ► The main limitation of this study—lack of stake-
holder involvement in identifying economic param-
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methodological platform for developing core outcome 
sets for different diseases and medical conditions.7
In recent years, economic evaluation has become an 
essential part of clinical studies to assist decision- makers 
with allocating resources in healthcare. Economic evalua-
tion involves a ‘comparative analysis of alternative courses 
of action in terms of both their costs and consequences’.8 
Therefore, economic evaluations necessarily need to 
collate information on both economic outcomes and 
health outcomes. Health outcomes represent health bene-
fits (eg, symptom relief, faster recovery or better quality of 
life) and may be either of a generic nature or specific to 
the condition being examined. Economic outcomes may 
include resource use (eg, number of prescriptions or days 
in hospital), costs (eg, cost of medication and diagnostic 
equipment) or combined metrics of costs and outcomes 
(eg, incremental cost- effectiveness ratio, probability 
of intervention being cost- effective). In the context of 
economic evaluations, preference- based health outcomes 
(eg, quality- adjusted life years or disability- adjusted life 
years) can be also considered as economic outcomes. To 
differentiate between health outcomes and economic 
outcomes, we will use the term ‘economic parameter’.
While currently there are no core parameter sets avail-
able for economic evaluations in asthma trials, a number 
of studies have identified a range of parameters used to 
evaluate costs and cost- effectiveness of healthcare inter-
ventions for people with asthma.4 9–12 Standardising 
these parameters is essential to ensure consistency in 
data collection, analyses, reporting and thus to enable 
valid comparison and evidence synthesis to appropriately 
inform resource allocation decisions.
We thus set out to develop a core parameter set for 
economic evaluation of asthma interventions. This paper 
reports results from the first stage of this process—a 
systematic literature review and an analytical framework. 
The aim of this stage was to identify economic parameters 
that are already in use and to establish a preliminary list of 
reported items to be considered for inclusion in the core 
parameter set. Due to the scope of the review, neither 
qualitative nor quantitative analyses would produce 
meaningful results. Therefore, we applied a realist review 
methodology, which combines quantitative and qualita-
tive approaches and focuses on contextual mechanisms 
that inform decisions and actions.13–15 The protocol for 
this review was published elsewhere.16
METHODS
Research strategy
The development of economic core parameter will be 
conducted in three stages. The first stage (described 
in this paper) includes a systematic literature review to 
determine what economic parameters are already in use 
and to establish a preliminary list of reporting items to be 
considered for inclusion in the core parameter set. In the 
second stage, we will use Delphi methodology to deter-
mine which economic parameters should be included 
in effectiveness studies. A national expert panel will be 
convened for round- table discussions including a wide 
range of stakeholders (healthcare professionals, people 
with mild to severe and brittle asthma as well as parents, 
relatives and carers of people with asthma) to identify 
important economic parameters. In the third stage, an 
international workshop will be convened to discuss the 
applicability of the Delphi- generated core economic 
parameter set across international settings and relevant 
disciplines.
Systematic literature review
The systematic literature review was based on the realist 
review methodology13–15 and included a number of non- 
sequential, iterative and overlapping components, such 
as developing an analytical framework for the realist 
review; systematic literature review of economic param-
eters; identifying and categorising economic parameters; 
producing preliminary list of core economic parameters. 
The realist methodology uses a mixed methods approach 
(both quantitative and qualitative) to addressing rela-
tionships between context, mechanisms and outcomes. It 
asks the question ‘What works for whom, in what circum-
stances and why?’13 The realist approach has been used 
to analyse the effectiveness of complex interventions in 
healthcare.15 In this study, we applied the realist frame-
work to address the questions: What economic parameters 
are used in asthma studies? For what type interventions 
and populations? In what kind of settings? From what 
stakeholder perspectives? A systematic literature review 
was conducted according to the protocol described 
elsewhere.16
Literature searches
We conducted literature searches using PubMed, the 
Cochrane Database of Systematic Reviews (CDSR), the 
Database of Abstracts of Reviews of Effects (DARE) and 
the Health Technology Assessment (HTA) Library for 
the period January 1990 to January 2019 and the NHS 
Economic Evaluation Database (EED) for the period 
January 1990 to March 2015 (stopped updating). Titles 
and abstracts were searched for inclusion of the Medical 
Subject Headings (MeSH) term ‘asthma’ as well as 
health economic key terms such as ‘economic’, ‘cost’ 
and ‘resource’ (online supplemental appendix 1). More 
information about the search strategy is provided in the 
published protocol.16 Records from different databases 
were merged and duplicate publications were removed.
Study selection
Study selection was conducted by three reviewers 
(including a researcher with experience of asthma) and 
comprised of two stages. In the first stage, the titles/
abstracts were screened according to the prespecified 
checklist (online supplemental appendix 2) to ensure 
that the selected studies reported economic parame-
ters, included the relevant population, and were written 
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studies that fulfilled the above criteria as well as studies 
classified as ‘unsure’ in the first stage. Studies were 
excluded at this stage if they did not report economic 
parameters, or included people with comorbidities or if 
the full text of study was not available. We also excluded 
studies conducted with children <5 years (due to chal-
lenges of confirmation of asthma diagnosis) and adults 
>65 years (who are likely to have a COPD–asthma overlap 
syndrome), in accordance with the protocol for the 
systematic review.16 Studies including children <5 years or 
adults >65 years among other age groups were marked as 
‘unsure’ for further scrutiny. On data extraction, it was 
found that studies including children <5 years and adults 
>65 years along with other age groups comprised more 
than a half of identified publications. Consequently, 
a decision was made to include these studies in the 
systematic review, as this reflects the real- world research 
context in which a core economic parameter set would 
be required. Any discrepancies regarding whether a study 
was relevant for inclusion in the review were resolved via 
involving the third reviewer.
Ideally, in the realist synthesis, no literature should be 
excluded,15 unless the paper is not relevant, or provides 
insufficient information. Therefore, we assessed the 
studies with respect to their relevance rather than scien-
tific rigour (research question, validity, generalisability 
etc). This approach is consistent with our aim to identify 
economic parameters that are already in use. However, 
we excluded studies which provided insufficient informa-
tion about economic parameters (eg, reported total costs, 
but did not specify what these costs included). Figure 1 
shows a diagram depicting the flow of papers through the 
selection process.
Data extraction
Data extraction was conducted by three researchers. All 
identified economic parameters were tabulated together 
with the major study characteristics: population, age, 
asthma severity, number of subjects, country, setting, 
type of study, type of intervention/comparators, type of 
economic evaluation, perspective of economic evaluation, 
costs, sources and instruments used to collect economic 
parameters
Identifying economic parameters
Economic parameters were identified through term 
search in Microsoft Excel 2016 using wildcards and 
keywords (detailed in online supplemental appendix 
3). Identified parameters were then aggregated into 11 
resource groups according to their explicit and implicit 
meaning. For example, economic parameters such as 
‘accident and emergency’, ‘emergency department’, 
‘emergency room’, ‘intensive care unit’, ‘ambulance’ and 
‘out- of- hours visits’ were thought to represent the same 
group ‘emergency care’. Aggregating parameters into 
resource groups was necessary to reduce the number of 
parameters to enable the realist synthesis.
Ranking economic parameters
Economic parameters were allocated to 1 of 11 resource 
groups: ‘primary care’; ‘secondary care’, ‘emergency 
care’, ‘informal care’, ‘medication’, ‘medical devices’, 
‘diagnostics’, ‘work’; ‘school’, ‘healthcare delivery’ and 
‘health utility’. For example, if a study- reported contacts 
with primary care doctors and nurses, these were counted 
as two outcomes, allocated to ‘primary care’. Results were 
presented as a frequency of using economic parameters 
for each resource group.
A ranking of resource groups was conducted to iden-
tify the most frequently used parameters, which can be 
considered for inclusion in the core parameter set. The 
ranking was based on parameter counts. Some studies 
used more than one economic parameter belonging to 
the same resource group. The ranking was conducted 
in two ways: (1) ranking resource groups across all 
studies included in the systematic review and (2) ranking 
resource groups among studies with different types on 
interventions, study designs, population groups, settings 
and stakeholder perspectives (see the Analytical frame-
work section).
Analytical framework
An analytical framework was developed using the concep-
tual framework analysis,17 which included the following 
steps:
i) Initial scoping using group discussions with stake-
holders and reviewing the literature.
ii) Identifying and naming the concepts.
iii) Deconstructing and integrating the concepts.
iv) Synthesising concepts into a theoretical framework.
Figure 1 Flow diagram showing the process of identifying 
and selecting relevant studies. DARE, Database of Abstracts 
of Reviews of Effects; HTA, Health Technology Assessment; 
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The initial scope for the analytical framework was iden-
tified from round- table discussions within the research 
team. Initial discussions were carried out at the Asthma 
UK Centre for Applied Research Methodology Work-
shop ‘Maximising Information from Empirical Studies’ 
(London, 23 January 2017). Workshop discussions set 
out to understand the rationale behind the choices of 
economic parameters. Subsequent discussions were 
focused on identifying contexts in which different 
economic parameters were used (eg, population age, 
asthma severity, study characteristics, type of economic 
analysis). The relationship between different contexts 
was analysed, and the contexts were integrated into 
framework domains. The hierarchy between framework 
domains was established and the domains were arranged 
into an analytical framework.
Patient and public involvement
Patients or the public were not involved in the design, or 
conduct, or reporting or dissemination plans at this stage.
RESULTS
Selected studies
Literature searches identified a total of 3011 entries 
before checking for duplicates (figure 1). The PubMed 
searches were set deliberately broad and included, along-
side specific terms such as ‘asthma’ and ‘economic’, a 
full range of general terms associated with healthcare 
resources, for example: ‘clinician’, ‘nurse’, ‘emergency’, 
‘attendance’. These searches generated a large number 
of studies which did not include economic parameters. 
Therefore, our further searches of CDSR, NHS EED, 
DARE and the HTA Library included mainly economic 
terms such as ‘economic’, ‘cost’, ‘resource’, ‘service’, 
‘productivity’ and so on. Removing duplicates generated 
2531 publications and abstracts were screened using the 
predefined checklist.16 Approximately 81% of publica-
tions were excluded since these were not economic eval-
uations (eg, clinical effectiveness studies, service delivery 
studies, editorials, protocols or methods papers). We 
also excluded papers that were not in English (n=43), 
included patients with comorbidities (n=8) or non- 
confirmed asthma (n=3). The remaining 423 studies 
were selected for full- text screening. Out of these, the 
text was not available for 14 publications; 152 were not 
full- size papers or did not report economic parameters 
(eg, abstracts, commentaries, editorials, reviews); 26 
studies were excluded due to population characteristics 
(included only children <5 years, adults >65 years old 
or people with comorbidity); 4 publications were not 
in English; 3 reported parameters from the same study. 
Economic parameters were extracted for 224 studies 
(listed in online supplemental appendix 4).
Characteristics of selected studies
The summary characteristics of studies included in the 
systematic review are shown in table 1. The majority 
Table 1 Summary characteristics of studies included in the 
systematic review (N=224)
Study characteristics N %
Country
  Europe (including Denmark, Finland, France, 
Germany, Ireland, Italy, Netherlands, Spain, 
Sweden, Switzerland, UK)
83 37
  USA 82 37
  Canada 20 9
  Multinational 19 8
  Other 20 9
Population
  Adults only 68 30
  Children 46 21
  Adults and children 75 33




  <100 19 8
  100–1000 95 42
  >1000 56 25
  Not specified (including economic models) 54 24
Asthma severity
  Mild 41 18
  Moderate 53 24
  Severe 50 22
  Other classification (including allergic, acute, 
persistent, uncontrolled)
56 25
  Not specified 99 44
Type of study
  Cohort study 83 37
  RCT 75 33
  Economic model 51 23
  Survey 10 4
  Literature review 6 3
Type of intervention
  Medication 107 48
  Procedures 28 13
  Educational interventions 21 9
  Tests 8 4
  Other interventions (eg, environmental, 
adherence)
3 1
  Non- interventional studies (eg, surveys, 
cost- of- illness study)
57 25
Perspective of economic analysis
  Healthcare provider 122 54
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(82%) was conducted in the USA, Europe (including the 
UK) and Canada. Studies undertaken in other countries 
(Australia, Brazil, Columbia, India, Japan, Thailand and 
Turkey) comprised 9% of identified studies. Approxi-
mately 8% of the studies were multinational.
Approximately a third of selected studies (33%) 
involved both adult and child participants. Thirty per cent 
of studies included only adults and 21% studies included 
only children. Population age was not specified in 16% of 
papers, including those based on economic models. The 
number of participants varied in wide range: 8% of studies 
included <100 individuals, 42% included 100–1000 indi-
viduals and 25% included >1000 individuals. Sample size 
was not specified in 25% of studies, including economic 
models, systematic reviews and cost- of- illness studies. With 
respect to asthma severity, the majority of studies included 
mixed populations. Participants with mild, moderate and 
severe asthma were presented in similar proportions 
(14%, 18% and 17%, respectively). However, a number of 
studies used different asthma severity classifications, for 
example, Global Initiative for Asthma classification (inter-
mittent, mild persistent, moderate persistent and severe 
persistent) or British Thoracic Society/Scottish Intercol-
legiate Guidelines Network classification (mild, moderate, 
severe and life- threatening). A substantial proportion of 
studies (44%) did not specify asthma severity. In terms of 
study design, 37% were cohort studies, 33% randomised 
controlled trials, 23% economic models and 7% were 
population- level surveys and literature reviews. Half 
were conducted from a healthcare provider perspective 
(included costs to healthcare system), 27% considered 
a societal perspective (eg, included school absence or 
parental days off work); 15% pursued a third- party payer 
perspective (eg, included health insurance claims) and 
only 2% considered patient or employer perspectives 
(eg, included costs to patients or employers). The most 
common type of economic evaluation was cost analysis 
(41%), followed by cost- effectiveness analysis (36%) and 
cost utility analysis (18%). Other types of economic anal-
yses (cost benefit, cost consequences etc) were used in 
less than 7% of studies.
Economic parameters were measured using wide range 
of instruments: study records (eg, preference- based and 
resource use questionnaires, diaries, case report forms) 
38%; registries and databases (eg, primary care records, 
hospital databases, medical insurance claims) 33%; 
published literature (eg, research papers, systematic 
reviews, meta- analyses, guidelines, tariffs) 22%; popula-
tion surveys (6%); expert panels (1%).
Characteristics of economic parameters
We identified 65 economic parameters which we aggre-
gated into 11 groups, each containing from 3 to 10 
items: medication, primary care, secondary care, emer-
gency care, diagnostics, drug delivery devices, healthcare 
delivery, informal care, work productivity, school activity 
and health utility (table 2).
Medication use was the largest group of economic 
parameters, capturing use of asthma medication (eg, long- 
acting beta agonists, short- acting beta agonists, inhaled 
corticosteroids, allergen immunotherapy and mono-
clonal antibodies), combination therapies, concomitant 
medication, treatment of drug adverse events and over- 
the- counter medication.
Primary care parameters included scheduled and 
unscheduled contacts with general practitioners and 
nurses (face- to- face appointments, telephone contacts 
and home visits), specialty consultations (eg, chest physi-
cian, allergy/internal medicine specialist or ENT doctor), 
acupuncture and physiotherapy and medical claims. 
Specialty consultations can be also provided as outpatient 
hospital appointments, depending on the healthcare 
system. Where outpatient/hospital appointments were 
not specifically mentioned, we allocated specialty consul-
tations to primary care.
Secondary care parameters were used to measure 
hospital- based care, including outpatient appointments, 
hospital admissions and readmissions, hospital supplies, 
room charges and medical claims.
Emergency care parameters included ambulance calls 
and attendances, emergency department visits, intensive 
care costs and out- of- hours contacts. While emergency 
services are mainly provided by the secondary care sector, 
these are usually analysed as a separate group.
Study characteristics N %
  Third- party payer (eg, insurance companies, 
managed care organisations)
39 17
  Other perspectives (eg, patients, employer) 6 3
  Not specified 21 9
Type of economic analysis
  Cost analysis 94 42
  Cost effectiveness 84 38
  Cost utility 41 18
  Cost benefit 6 3
  Cost consequences 2 1
  Cost minimisation 2 1
  Other analysis (eg, resource use, literature 
review of economic analysis)
4 2
Sources of economic outcomes
  Study records 89 40
  Registries and databases 77 34
  Published sources 51 23
  Population surveys 13 6
  Expert panels 3 1
  Not specified 2 1
*Rounded to the nearest whole number. Some studies may belong 
to several groups, therefore percentages may not add to 100%.
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Diagnostics parameters capture resources and costs 
associated with asthma diagnosis and monitoring, such 
as procedures (eg, peak expiratory flow measurements), 
equipment (eg, exhaled nitric oxide monitor) and labo-
ratory tests (eg, IgE test).
Drug delivery parameters apply to medical devices used 
to deliver drugs directly to the airways. These include 
inhalers (pressurised metered dose inhalers, breath- 
actuated aerosol inhalers and dry powder inhalers), nebu-
lisers (which create mist breathed in through a mask or 
mouthpiece), spacers (extension devices that are placed 
at the interface between the patient and the inhaler) 
and valved holding chambers (extensions which allow 
inhalation and prevent exhalation into the chamber). 
Parameters related to drug delivery devices include cost 
and number of prescribed items and cost of respiratory 
therapy.
Healthcare delivery parameters include time and cost 
associated with attending healthcare appointments (eg, 
travel and waiting), healthcare programme delivery costs 
(eg, telemetry) and willingness to pay for services.
Informal care parameters capture burden and costs 
related to care (usually unpaid) provided by family 
or friends to people with asthma. These parameters 
include caregivers’ time off work, productivity losses, 
early retirement, housekeeping costs. We also allocated 
to this group household modifications (eg, air filters 
or dehumidifiers), due to small number of such 
parameters.
Work productivity parameters capture the effect of 
asthma on work activity, for example, time off work due 
to illness, income loss, disability payments and premature 
retirement.
School activity parameters capture the effect of asthma 
on school attendance, number of sickness episodes, 
school clinic consultations, cost of school nurses and 
school fees lost.
Health utility parameters are preference- based health- 
related quality of live values, which people attach to the 
overall health status. We included in this group quality- 
adjusted life years and years lived with disability. It should 
be mentioned that health utilities are used as health 
outcomes as well as economic outcomes in asthma studies.
Figure 2 shows the proportional use of economic 
parameters in asthma studies. Secondary care param-
eters were the most frequently used group (24%), 
followed by primary care (20%) medication use 
(18%), emergency care (11%) and work (10%). Other 
parameter groups (informal care, school, diagnostics, 
healthcare delivery and health utilities) were found in 
0.5%–4% of studies.
Table 2 Economic parameters identified by the systematic review
Resource group Economic parameter
Secondary care Hospital admissions, duration of stay in hospital, use of hospital services/beds, supplies and room 
charges, outpatient visits/consultations, readmissions, medical claims
Primary care General practice visits, contacts with nurse, physiotherapy sessions, specialist consultations, home 
visits, telephone consultations, unscheduled consultations, physiotherapy sessions, acupuncture 
sessions, medical claims
Medication use Drugs number/dose/frequency/cost, number of items prescribed/number of prescriptions, net 
ingredient cost, combination therapies and concomitant medication, treatment cost of drug- related 
adverse events, pharmacy costs, cost savings from medication averted, pharmacy claims, over- the- 
counter medication, rescue/acute medication
Emergency care Emergency department visits and admissions, intensive care stay, ambulance calls and attendances, 
out- of- hours services
Work Time off work due to illness, number of sickness episodes, productivity loss due to absenteeism and 
presenteeism, lost income, workers’ compensations and disability payments, inability to perform 
usual activities, unpaid work, premature retirement
Diagnostics Diagnostic procedures, diagnostic equipment, laboratory tests
Health utility QALY, YLD, HR- QoL
Healthcare delivery Travel time/cost, time spent by patient attending hospital/clinic, time spent by accompanying person 
attending hospital/clinic, waiting time/cost, cost of care delivery programme, willingness to pay for 
services
School Days off school, number of sickness episodes, school fees lost, school clinic consultations, cost of 
school nurse
Informal care Time off work for caregivers, parents’/caregivers’ work productivity losses, loss of work/income for 
parents/caregivers, early retirement of caregivers, housekeeping costs,household modifications (eg, 
air filters, dehumidifiers)
Devices Type of inhaler device/cost, number of items prescribed, cost of respiratory therapy (nebuliser)
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Framework analysis
An analytical framework was developed to examine 
the use of economic parameters in different contexts 
of economic evaluation. The framework includes five 
domains (perspective of economic evaluation, interven-
tion, population, study design and study setting; figure 3) 
and is further described below alongside analysis of the 
identified economic parameters.
Perspective of economic evaluation reflects the stake-
holders’ viewpoint from which economic evaluation is 
conducted. Some studies adopt narrow perspectives such 
as that of patient or health insurance provider. Wider 
perspectives include those of society, healthcare and 
social care. The following perspectives were identified: 
healthcare provider (n=122); societal (n=68); third- party 
payer (eg, health insurance providers and government 
plans) (n=39); patient (n=5). Thirty- nine studies adopted 
multiple perspectives, such as healthcare provider and 
societal. In studies conducted from a healthcare provider 
perspective, the top three most frequently used parame-
ters were secondary care, primary care and medication 
use. In studies conducted from a societal perspective, 
these were included: primary care, secondary care and 
work. Studies which adopted a third- party payer perspec-
tive included secondary care, medication use and emer-
gency care among the most frequently used parameters 
(online supplemental appendix 5).
Intervention is a health technology under investigation 
which may or may not be compared with an alternative 
technology. The types of interventions used in asthma 
studies included medication (n=107), procedures (n=28), 
educational interventions (n=21), diagnostics (n=8), envi-
ronmental interventions (n=2), adherence interventions 
(n=1) and non- interventional studies (eg, surveys, cost of 
illness n=57). The most frequently used parameters for 
medication interventions were primary care, secondary 
care and medication use; for procedure interventions—
secondary care, primary care and emergency care; for 
educational interventions—secondary care, emergency 
care and primary care; for diagnostics interventions—
primary care, secondary care and diagnostics. The use of 
economic parameters in studies with different interven-
tions is depicted in figure 4. The full ranking of economic 
parameters is shown in online supplemental appendix 5.
Population refers to characteristics of study participants 
such as sample size, age, gender, severity of asthma and 
so on. We were able to isolate three age groups: chil-
dren (<18 years) (n=46), adults (18+years) (n=68) and 
a mixed population including both children and adults 
(n=75). More detailed breakdowns were not possible due 
to studies reporting aggregated age data. Secondary care, 
primary care, medication use and emergency care were 
the most frequently used parameters in all age groups. 
Studies with children also included parameters on school 
absence and informal care, while studies with adult popu-
lation reported sick leave, productivity loss, work absen-
teeism and presenteeism. Secondary care, primary care, 
medication use and emergency care were also the most 
frequently reported parameters in patients with different 
asthma severities (mild, moderate and severe asthma, 
online supplemental appendix 5).
Study design refers to the methods and procedures of 
data gathering. The most frequently used research designs 
were cohort studies (n=83), randomised controlled trials 
(n=75) and economic modelling studies (n=51). Other 
designs such as surveys and literature reviews were used 
in 16 studies. Secondary care, primary care, medication 
use and emergency care were the most frequently used 
parameters across different study designs (online supple-
mental appendix 5).
Setting refers to different sites, facilities and providers of 
health and social care, such as General practice, hospital, 
school, pharmacy and so on. The majority of experi-
mental studies was conducted in primary care settings 
Figure 2 Proportional use of economic parameters in the 
identified studies.
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(n=100) and secondary care settings (n=80). Secondary 
care, primary care, medication use and emergency care 
were the most commonly used economic parameters in 
these settings. A small number of studies were conducted 
in schools (n=9), community (n=7), pharmacy (n=4) and 
emergency setting (n=2). These studies also included 
work- related and school- related parameters (eg, sick 
leave, productivity loss, school absence) among the most 
frequently used parameters.
Preliminary list of core economic parameters
To derive a preliminary list of core economic parame-
ters used in past studies, we ranked 11 resource groups 
based on the frequency of usage of economic param-
eters. Parameters related to secondary care, primary 
care, medication use, emergency care and work (ranks 
1–5, table 3) comprised of 84% of all economic param-
eters used in asthma studies. The less frequently used 
parameters were related to diagnostics (4.2%), health 
utility (3.5%), healthcare delivery (3.4%), informal care 
(2.5%), school (2.4%) and devices (0.5%). Additional 
ranking was performed using the analytical framework to 
categorise economic parameters with respect to different 
types of interventions, populations, study designs, settings 
and stakeholder perspectives (table 4). The ranking 
shows that groups representing secondary care, primary 
care, medication use, emergency care and work produc-
tivity (ranks 1–5) were the most frequently used groups 
of economic outcomes across different studies. These 
followed by diagnostics (median rank 6), health utility 
and healthcare delivery (median ranks 8), school and 
informal care (median ranks 9), and drug delivery devices 
(median rank 11).
The above results suggest that economic parameters 
related to secondary care, primary care, medication use, 
emergency care and work productivity can be considered 
Figure 4 Use of economic parameters in studies with 
different types of interventions.
Table 3 Ranking of economic parameters according 
to the frequency of their usage in studies included in the 
systematic review
Parameter group Count of use % of total use Rank
Secondary care 246 22.8 1
Primary care 215 19.9 2
Medication 185 17.1 3
Emergency care 153 14.2 4
Work 102 9.5 5
Diagnostics 45 4.2 6
Health utility 38 3.5 7
Healthcare delivery 37 3.4 8
Informal care 27 2.5 9
School 26 2.4 10
Devices 5 0.5 11
The ranking was based on parameter counts. The total number of 
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as the core parameters in asthma studies. Parameters 
related to asthma diagnostics, drug delivery devices, 
healthcare delivery, informal care, school and health 
utility can be considered as supplementary parameters, 
which apply to certain types of interventions, popula-
tions, study designs or stakeholder perspectives.
DISCUSSION
This paper describes the first step in developing core 
parameter sets specifically for asthma- related economic 
evaluations. Based on the systematic literature review, 
we identified the most frequently used economic param-
eters, classified these parameters into resource groups 
and applied ranking of resource groups to derive a 
preliminary lists of parameters for inclusion in the core 
and supplementary parameter sets. Our examination of 
past research demonstrates a wide range of parameters 
used for measuring resource utilisation, costs and cost- 
effectiveness of healthcare interventions for people with 
asthma. In total, 65 different economic parameters were 
used in 224 studies included in this review. The most 
frequently used parameters were those capturing use of 
specialised hospital- based (secondary) care and general 
practice- based (primary) care, followed by parameters 
quantifying the use of medication, emergency services 
and work activity. The above parameters can be poten-
tially considered as core economic parameters in future 
asthma studies.
Approaches to standardising economic parameters
The methodology of developing core outcome sets is 
well developed and thoroughly described in the litera-
ture.4 6 18–21 It includes a range of qualitative techniques 
such as systematic literature reviews, interviews with stake-
holders, group discussions, surveys, conceptual frame-
works, Delphi studies and combinations of these.4 18 19 21
The process of developing core outcome sets usually 
includes following steps6:
1. Defining a scope for developing core outcome set.
2. Identifying existing knowledge (eg, using systematic 
literature reviews).
3. Involving key stakeholders (eg, using surveys, inter-
views and focus groups).
4. Achieving consensus (eg, using Delphi process).
5. Validating core outcome set (eg, using reviews and 
feedback).
6. Implementing core outcome set.
While our work follows the approach set out by 
Willamson and coauthors,6 which specifically focuses on 
developing core outcome sets for defined clinical areas, 
we acknowledge alternative approaches to generalise the 
use of economic parameters in clinical studies.
The Consolidated Health Economic Evaluation 
Reporting Standards initiative proposed a checklist of 
items to be reported in economic evaluations of health-
care interventions.22 This included economic parameters 
such as incremental costs and effectiveness estimates, 
health utility, characteristics of uncertainty and hetero-
geneity. However, the checklist is necessarily general in 
nature because it aims to address all economic evalua-
tions and it primarily focuses on improving reporting 
standards and thus provides limited guidance on the 
choice of parameters to be used.
The Database of Instruments for Resource Use Measure-
ment project aimed to develop a database of instruments 
for collecting economic parameters in clinical trials.23 
The database currently contains 84 validated and non- 
validated instruments, including resource use ques-
tionnaires for asthma studies (http://www. dirum. org/ 
instruments/ all). Included questionnaires are unlikely 
to be used off the shelf, but they provide a good starting 
point in selecting and standardising parameters for new 
studies.
The Outcome Measures in Rheumatology initiative 
focuses on developing effectiveness outcomes for rheu-
matology studies and its analytical framework incorpo-
rates economic outcomes such as direct, indirect and 
intangible costs and impacts on society, individuals and 
healthcare system.24 It recommends including at least 
one domain describing resource use in clinical trials, but 
it does not specify the set of economic parameters to be 
collected.
Within the asthma area, the first attempt to standardise 
economic outcomes was undertaken at a National Insti-
tutes of Health workshop in March 2010.12 The outcomes 
were classified as core (required in future studies), supple-
mental (used according to study aims and standardised) 
and emerging (requiring validation and standardisa-
tion). Core economic outcomes included asthma- specific 
hospital admissions, emergency department visits, outpa-
tient visits and medication use. Supplemental parameters 
included primary care visits (scheduled and unsched-
uled), specialty and respiratory care; work and school 
absences. The emerging parameters were identified as 
patient- initiated remote care event (such as e- mail or 
telephone consultations), student achievements and test 
results. However, the above study12 did not attempt to 
characterise the usage of economic parameters in asthma 
studies, as we have done here.
Realist review approach
We conducted a mixed- methods research that included a 
systematic literature review and an analytical framework. 
The methodology was based on a realist review approach 
to address the complexity of contexts and the heteroge-
neity of economic parameters.13 14 Realist reviews have 
been previously used to analyse the effectiveness of 
complex policy interventions in health and social care, for 
example, providing school meals,25 internet- based health 
education,26 smoking cessation27 and managing diabetes 
in people with dementia.28 We felt that the realist meth-
odology can be equally applied to deriving core param-
eter sets, given that neither qualitative nor quantitative 
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We used an analytical framework analysis to identify 
contextual factors, which inform the choice of economic 
parameters in asthma studies. These factors were type of 
intervention, study design, target population, research 
setting and stakeholder perspective. The above frame-
work was used to analyse economic parameters identi-
fied by the systematic literature review. The process of 
developing the framework was non- sequential and itera-
tive in nature; the framework was changing as the new 
evidence was uncovered. The analytical framework was 
subsequently used to rank economic parameters identi-
fied by the systematic review. Sixty- five economic parame-
ters were grouped into 11 economic categories to enable 
the analysis. This allowed identifying the most frequently 
used economic parameters across different intervention, 
study designs, target populations, research settings and 
stakeholder perspectives. These categories included 
parameters representing secondary care, primary care, 
medication use, emergency care and work and can be 
identified as core economic parameters. Supplementary 
parameter categories such as health utility, healthcare 
delivery, school, informal care and devices could apply 
to a certain types of studies (eg, community- based and 
school- based interventions, uncontrolled asthma, organi-
sational changes and drug delivery devices).
CONCLUSIONS
1. The systematic literature review identified a wide range 
of economic parameters applied in asthma studies to 
capture the usage of healthcare services, medication, 
work and school activities, informal care and health 
utility. Multiple parameters were used to measure the 
same economic category (eg, work activity or medica-
tion use).
2. Due to large number of economic parameters and a 
variety of economic categories identified in asthma 
studies, an analytical framework is required to enable 
data synthesis. The mixed- methods analysis based on 
the realist review methodology is a useful tool for sys-
tematising economic parameters.
3. Identifying contextual factors that inform the choices 
of economic parameters in asthma studies and apply-
ing ranking approach can be helpful in identifying 
economic parameters for inclusion in the preliminary 
core outcome set.
4. Economic parameters depicting the use of secondary 
care, primary care, medication, emergency care and 
work productivity can be considered as core econom-
ic parameters, since they apply to different types of 
studies. Parameters including diagnostics, healthcare 
delivery, school activity, informal care, medical devices 
and health utility apply to a particular type of study (or 
research question) and, thus, can be recommended as 
supplemental parameters.
Study limitations
This study has following limitations:
1. Limited range of data sources. The study focused 
on peer- reviewed studies and did not include other 
data sources (eg, online forums, interviews and focus 
groups).
2. Ranking based on frequency of usage of economic pa-
rameters was the only criteria for inclusion in the pre-
liminary list of core outcomes. Other inclusion criteria 
can be considered, for example, based on stakeholder 
opinions or on consensus of opinions.
3. Lack of stakeholder involvement in identifying rele-
vant economic parameters (eg, patients and health-
care professionals).
These limitations will be addressed in the next stage 
of developing economic parameter sets—refining core 
economic outcomes using Delphi study. It will involve a 
national panel including healthcare professionals, people 
with asthma, parents, relatives and carers of people with 
asthma. Each participant will have an opportunity to rank 
each parameter as important or unimportant to them as 
well as to nominate economic parameters of potential 
relevance that have not been identified from past studies. 
After the first round, any parameters that are universally 
considered to be unimportant will be removed. In the 
following round, participants will be given a feedback on 
how other stakeholders ranked the remaining parame-
ters and have the opportunity to alter their ratings. On 
reaching consensus on parameters sets, an international 
workshop will be organised to discuss the applicability of 
proposed sets for asthma studies nationally and world-
wide. To ensure uptake of the core parameters sets, we 
will engage with clinical guideline developers, research 
funders, trial registries, ethics committees, patients and 
public representatives.
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